Insmeds binary event will surely affect the stock , but if there is ??? (below) a correction after the event...when are revenues. Elliot wavers and Sentiment is very high, some estimates as high as before the last crash.
Margin at all time highs, calls hit this last bio correction.
Witness some of these moves...( trades I called in from Mexico but didnt participate) Fuel cell ! Plug ...moves reminiscent of 2000! ....when there is constant talk among the message boards that ! - a double from here! is a strong marker for a top. Buffett thinks so Good Luck
This is the long awaited real biotech correction. Not going to stick around to see if Insmed gets back to the 50 day
Too much fun! 3 trades today - all shorts ...surfs up kids! I'm so amused,I'm laughing all the way to the bank
and therein lies the risk. If Insmed is req to do a P three for NTM after discussions,the stock will really dump. With such an important binary event,I stand clear of bios in this situation unless the pipeline is rich, Insmeds is not. You are not Ppants by chance ? GL
This mornings short was obvious. Technically INSM has broken important support. 16.01 is the next target but I not dare because I protect profits. ( margin calls will loom for some on the wrong side of the trade). Could traders take INSM to 14.97 test?...then drive it back to $22 having made money both ways?The longs are the shorts and the fudkvnlevinchdorain clowns dont have a clue.
I'm so amused, I'm laughing all the way to the bank
to another investor.
No, I did not say 7 dollars unless the trial failed and no one has any knowledge of that result. I have posted that the trial results,like the CF results may be good but not the Holy grail of immediate filing and drug launch.Will Lewis has always spoken of the possibility of NTM "needing additional work" to get to the pathway for filing. This mornings PR (last paragraph) alludes to the possibility of additional discussions trials work or data discovery.If the results are "encouraging" ( company's speak) Insmed will be on their way to 40 dollars,but I place odds on the reality of the drug approval process and the deliberate almost painful reality of the pathway to bring this board into biotech reality.I have never wished that Insmed or any bio not succeed to help those afflicted but reality is something the usual suspects here need, We shall see.
Following the release of these data, we expect to have discussions with regulatory authorities in the U.S. and Europe regarding a path forward to filing for approval. In the interim, we have initiated a comprehensive education campaign to raise awareness of NTM and to increase accurate and early diagnosis," added Mr. Lewis.
poor Evelyn.. perhaps she will update us soon on her TB work! Bravo!
fudfighter3 • Nov 3 - "I'm currently in discussion with the global Stop TB Partnership, advising them how they should redesign their various therapeutic regimens now that Arikace is available.When they've finally grasped what they should be doing I'll get in touch with Insmed and give them the benefit of my advice"
amused.The latest "basher" knows more than the tons of fudoriankvncmcdd garbage answers. 140characters is saying many correct things but carefully choosing his terms. Insmed MAY EVENTUALLY file for CF in the states but it may be years. Novartis is a large pharma with pricing power over Insmed ..... also in that 10k is that Insmed will sell Arikace all by themselves! Well the company said it! so it must be true! - No way! Good Luck
Confusing off label and scripts ,Evelyn posts that US doctors will write a script
for a FDA unapproved drug in another country where it may be available is fuds usual blcht.
For NTM patients and those that invest lets hope Insmed phase2B is successful Good Luck
Ignore the personal attacks from the poster fudfighter( who is also b- leagured /blaspd31 ) acronym ....
Insmed has already received accelerated approval from the FDA should the results be "encouraging - CEO Lewis). Obviously the co knows where the bar has been set.Results from NTM should be released in the next couple of weeks. Good Luck
Insmed declined to do a trial in the U.S for CF..imOpinion, the trail would have been longer , so the company gambled -and lost- when the results were uncompelling - non inferior.
Its not nice to try and skirt the FDA - they are unforgiving.
1 trade and out today, some of us actually have families and a life. Good Luck
Much of what the poster wraps around the Podinhaler is true. Approved in most countries around the world
and yes given socialized medicines seal of cost approval,Novartis has a winner,as well as a 2 year head start on Arikace.The drug will be completely entrenched when Arikace arrives in Europe and Canada. As of now there is no US Market for Arikace as Insmed has so far they do not intend to file Arikace for CF
Do they call the registries in Europe "formularies" or is that the US?
Has 140 seen the test results and can tell the future of the label ? No, no one has,Insmed hasn't even filed in Europe and Canada. Does 140 know the cost that Will Lewis has said Insmed must meet to be competitive?
So the info splattered here is somewhere in between but one point is very clear. Arikace for CF is an ORPHAN which is a small market, a competitive market and Insurance companies (bakwardpalms comment this morning) would rather cover at a lower cost than care how well a patient does. Ill let the poster who has riled the crowd continue ,but until the results of NTM, most DD is yet to be defined
If I spent 4 mins here yesterday it was 3 min too many,there was 1 post worthwhile.This is kevie and Evelyns life who's records speak for themselves. I am not short, I am positive but not invested here .Evelyn sits here it looks like 12 hours a day praying the next impostor is Califfla!..............amazin,simply amazing. Off to trading....
If I spent 5 mins here yesterday it was 4 min too many,there was 1 post worthwhile.This is kevie and Evelyns life who's records speak for themselves. I am not short, I am positive but not invested here .Evelyn sits here it looks like 12 hours a day praying the next impostor is Califfla!..............amazin,simply amazing. Off to trading....
ps- the short interest has remained the same for months - guess why
Ill stand by the first "GUESS", that Insmed will need additional work..... IF a phase3 happens,it will be a catastrophe for the share price... discussions have been moved out an additional 3 months
and now we wont know how long the delay is till the second quarter - ) ... MVIS
Awwww kvn and Evelyn were so busy yesterday ... I'm so amused I'm laughing all the way to the bank
Now the ignore ..
Thanks,Kinkey. So the company at the end of last year got a clearer picture of the discussions and the possible timeline,moving out to mid year and the possibility of either another trial or "additional work" ( they may request more trial data before they decide , say a 6 month delay.Good DD. "top line data" will be the results of the trial over the next 5 weeks and Insmed will paint a pretty pic.Will Lewis did an exemplary job with Arikace for CF even though the drug failed to meet the compelling bar. Good Luck
Another even bigger change is on page 13. In the past Insmed had said they would be finished discussions with the FDA and EU regarding their path to approval BY THE END OF the first quarter NOW- .The change is : Q2: Continued dialogue with EMA and FDA regarding NTM regulatory path
● Q2: ● Exact timing dependent on NTM data and EMA regulatory dialogue
betcha I nailed it months ago ...bash away kids, but investors take note.
Watch the market for a turn, the trading looks like a headfake - last one . Good Luck